DOCSLIB.ORG

WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: sachusetts 02460 (US). FUTATSUGI, Kentaro; 97 West C07D 471/04 (2006.01) A61K 31/519 (2006.01) Main Street, Unit 29, Niantic, Connecticut 06357 (US). C07D 473/32 (2006.01) A61K 31/52 (2006.01) HEPWORTH, David; 282 Sudbury Road, Concord, M as C07D 487/04 (2006.01) A61P 3/10 (2006.01) sachusetts 01742 (US). KUNG, Daniel W.; 289 Laurel- C07D 519/00 (2006.01) wood Drive, Salem, Connecticut 06420 (US). ORR, Suvi; 16 Seabreeze Road, Old Saybrook, Connecticut 06475 (21) International Application Number: (US). WANG, Jian; 164 White Street, Belmont, Mas PCT/IB20 13/052404 sachusetts 02478 (US). (22) International Filing Date: (74) Agents: KLEIMAN, Gabriel L. et al; Pfizer Inc., 235 26 March 2013 (26.03.2013) East 42nd Street, New York, NY 1001 7 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/621,144 6 April 2012 (06.04.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, New York, New York 10017 (US). KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (72) Inventors: AHN, Kay; 33 Hill Street, Lexington, Mas NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, sachusetts 02421 (US). BOEHM, Markus; Fox Avenue, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, Fishers Island, New York 06390 (US). CABRAL, Shawn; TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 66 Latham Street, Groton, Connecticut 06340 (US). ZM, ZW. CARPINO, Philip A.; 1603 Centre Street, Newton, Mas [Continued on nextpage] (54) Title: DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS (57) Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H- FIG. 1 imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylgly- cerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein. o 2-Theta - Scale FIG. 1. X-ray powder diffraction pattern of Example 109-B. w o 2013/150416 A i II II II I il Illlll III I II I II III III III II I II (84) Designated States (unless otherwise indicated, for every — as to applicant's entitlement to apply for and be granted Mnd of regional protection available): ARIPO (BW, GH, apatent (Rule 4.1 7(H)) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — as to the applicant's entitlement to claim the priority of TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, the earlier application (Rule 4.1 7(iii)) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, — of inventorship (Rule 4.17(iv)) LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, ML, MR, NE, SN, TD, TG). — with international search report (An. 21(3)) Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.1 7(i)) DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FIELD OF THE INVENTION The present invention relates to new pharmaceutical compounds, pharmaceutical compositions containing these compounds, and their use to inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2). BACKGROUND OF THE INVENTION Triglycerides or triacylglycerols (TAG) represent a major form of energy storage in mammals. TAG's are formed by the sequential esterification of glycerol with three fatty acids of varying chain lengths and degrees of saturation. TAG synthesized in the intestine or liver are packaged into chylomicrons or very low-density lipoprotein (VLDL), respectively, and exported to peripheral tissues where they are hydrolysed to their constituent fatty acids and glycerol by lipoprotein lipase (LPL). The resultant non- esterified fatty acids (NEFA) can either be metabolised further to produce energy or reesterified and stored. Under normal physiological conditions, the energy-dense TAG remains sequestered in various adipose depots until there is a demand for its release, whereupon, it is hydrolyzed to glycerol and free fatty acids which are then released into the blood stream. This process is tightly regulated by the opposing actions of insulin and hormones such as catecholamines which promote the deposition and mobilization of TAG stores under various physiological conditions. In the post-prandial setting, insulin acts to inhibit lipolysis, thereby, restraining the release of energy in the form of NEFA and ensuring the appropriate storage of dietary lipids in adipose depots. However, in patients with type 2 diabetes, the ability of insulin to suppress lipolysis is ameliorated and NEFA flux from adipocytes is inappropriately elevated. This, in turn, results in increased delivery of lipid to tissues such as muscle and liver. In the absence of energetic demand the TAG and other lipid metabolites, such as diacylglycerol (DAG) can accumulate and cause a loss of insulin sensitivity. Insulin resistance in muscle is characterized by reduced glucose uptake and glycogen storage, whilst in the liver, loss of insulin signaling gives rise to dysregulated glucose output and over-production of TAG-rich VLDL, a hallmark of type 2 diabetes. Elevated secretion of TAG-enriched VLDL, so called VLDL1 particles, is thought to stimulate the production of small, dense low-density lipoprotein (sdLDL), a proatherogenic subtraction of LDL that is associated with elevated risk of coronary heart disease. Diacylglycerol acyltransferases (DGAT) catalyze the terminal step in TAG synthesis, specifically, the esterification of a fatty acid with diacylglycerol resulting in the formation of TAG. In mammals, two DGAT enzymes (DGAT1 and DGAT2) have been characterized. Although these enzymes catalyze the same enzymatic reaction their respective amino acid sequences are unrelated and they occupy distinct gene families. Mice harboring a disruption in the gene encoding DGAT1 are resistant to diet-induced obesity and have elevated energy expenditure and activity. Dgatl-/- mice exhibit dysregulated postaborpative release of chylomicrons and accumulate lipid in the enterocytes. The metabolically favorable phenotype observed in these mice is suggested to be driven by loss of DGAT1 expression in the intestine. Importantly, despite a defect in lactation in female Dgatl-/- mice, these animals retain the capacity to synthesize TAG suggesting the existence of additional DGAT enzymes. This observation and the isolation of a second DGAT from the fungus Mortierella rammaniana led to the identification and characterization of DGAT2. DGAT2 is highly expressed in liver and adipose, and unlike DGAT1, exhibits exquisite substrate specificity for DAG. Deletion of the DGAT2 gene in rodents results in defective intrauterine growth, severe lipemia, impaired skin barrier function, and early post-natal death. Due to the lethality caused by loss of DGAT2, much of our understanding of the physiological role of DGAT2 derives from studies performed with antisense oligonucleotides (ASO) in rodent models of metabolic disease. In this setting, inhibition of hepatic DGAT2 resulted in improvements in plasma lipoprotein profile (decrease in total cholesterol and TAG) and a reduction of hepatic lipid burden which was accompanied by improved insulin sensitivity and whole-body glucose control. Although the molecular mechanisms underlying these observations are not fully elucidated, it is clear that suppression of DGAT2 results in a down-regulation of the expression of multiple genes encoding proteins involved in lipogensis , including sterol regulatory element-binding proteins 1c (SREBPIc) and stearoyl CoA-desaturase 1 (SCD1). In parallel, oxidative pathways are induced as evidenced by increased expression of genes such as carnitine palmitoyi transfersase 1 (CPT1). The net result of these changes is to decrease the levels of hepatic DAG and TAG lipid which, in turn, leads to improved insulin responsiveness in the liver. Furthermore, DGAT2 inhibition suppresses hepatic VLDL TAG secretion and reduction in circulating cholesterol levels. Finally, plasma apolipoprotein B (APOB) levels were suppressed, possibly due to decreased supply of TAG for lipidation of the newly synthesized APOB protein. The beneficial effects of DGAT2 inhibition on both glycemic control and plasma cholesterol profile support that this target might be valuable in the treatment of metabolic disease. SUMMARY OF THE INVENTION The present application is directed at compounds of Formula (I) wherein: A is CR6R7, O or S; B is a bond, oxetanyl, wherein m is 0, 1 or 2; p is 1, 2, 3 or 4 ; C and D are each individually selected from N, CH, CF and C(CH 3), wherein only one of C and D is N; R is -C(0)-heterocyclyl, -C(0)-NR 4R5, or a heteroaryl, wherein said heterocyclyl or heteroaryl is optionally substituted with 1 or 2 substituents selected independently from (CrC 4)alkyl, (C3-C6 )cycloalkyl, ( -C4)alkoxy, (C3-C6)cycloalkoxy, halo, hydroxy(Ci-C 4)alkyl, mono-N- or di-N,N-(Ci-C 4)alkylamino, mono-N- or di-N,N-(C3- C 6)cycloalkylamino, heterocyclyl, hydroxyl and cyano;
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Sous Forme De Sel De Calcium
    Nom molécule Abamectine Absinthe (teinture de) Acamprosate (sous forme de sel de calcium) Acarbose Acébutolol (sous forme de chlorhydrate) Acéclofénac Acéfylline heptaminol Acémétacine Acépromazine Acépromazine (sous forme de maléate) Acétate de calcium Acétate de magnésium (sous forme de tétrahydrate) Acétate de potassium Acétate de sodium Acétate de sodium (sous forme de trihydrate) Acétazolamide Acétylcholine (sous forme de chlorure) Acétylcystéine Acétylméthionine Acétylméthionine (sous forme de sel de magnésium) Achillée millefeuille Aciclovir Acide acétylsalicylique Acide acétylsalicylique (sous forme de carbasalate de calcium) Acide acétylsalicylique (sous forme de lysinate) Acide acétylsalicylique (sous forme de sel de sodium) Acide adipique Acide alendronique (sous forme de sel de sodium) Acide alginique Acide alginique (sous forme de sel de calcium) Acide aminocaproïque Acide ascorbique Acide ascorbique (sous forme de sel de calcium) Acide ascorbique (sous forme de sel de sodium) Acide aspartique Acide aspartique (sous forme de sel de calcium) Acide aspartique (sous forme de sel de magnésium) Acide aspartique (sous forme de sel de magnésium et de potassium) Acide aspartique (sous forme de sel de magnésium et de potassium dihydraté) Acide aspartique (sous forme de sel de magnésium tétrahydraté) Acide aspartique (sous forme de sel de potassium) Acide aspartique (sous forme de sel de potassium hémihydraté) Acide aspartique (sous forme de zinc) Acide benzoïque Acide benzoïque (sous forme de benzyle) Acide benzoïque (sous forme de
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization II International Bureau (10) International Publication Number (43) International Publication Date WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 513/04 (2006.01) A61P 3/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/542 (2006.01) A61P 25/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2014/058777 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 4 February 2014 (04.02.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/765,283 15 February 2013 (15.02.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New York, New York 10017 (US).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Slentrol; INN:Dirlotapide
    SCIENTIFIC DISCUSSION 1 SUMMARY OF THE DOSSIER Slentrol oral solution for dogs contains dirlotapide 5 mg/ml as the active substance. The active substance of Slentrol, dirlotapide, is a potent inhibitor of the microsomal triglyceride transfer protein (MTP). It works locally in the intestine by inhibiting the transfer of lipids into the bloodstream which indirectly produces an appetite suppressant effect. The benefits of Slentrol are its ability to reduce bodyweight in adult dogs when given in accordance with the approved treatment schedule, until the target body weight is reached. The treatment is given once daily directly into the mouth or on a small amount of food. The product can be administered with or without food. The most common side effects are one or more vomiting events, sometimes accompanied by signs of tiredness, disinterest in food or diarrhoea, which can reoccur occasionally during the course of treatment. The approved indication is: “As an aid in the management of overweightauthorised and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes and exercise practice.” 2. QUALITY ASSESSMENT Composition Slentrol oral solution contains 5 mg/ml dirlotapide as active substance. The only excipient is medium chain triglyceride (MCT) oil. Container longer Dirlotapide oral solution (5 mg/ml) is presented in 20 ml, 50 ml and 150 ml white polypropylene (PP) bottles fitted with a low density polyethylene (LDPE) bottle adapter. The bottles are closed with a child resistant (CR) closure. The system is suitable to protect the medicinal product from light exposure.
    [Show full text]
  • Evaluation of the Efficacy of IQV04 for Weight Loss in Overweight and Obese Dogs
    Evaluation of the efficacy of IQV04 for weight loss in overweight and obese dogs. Annika Bieze 3514870 Supervisor: Dr. R.J. Corbee Abstract Introduction: Overweight and obesity are worldwide problems. Because of the higher risk of associated diseases, it is better to prevent and treat overweight and obesity. Beside weight loss programs, there are different medications and supplements available. After promising results from human health studies on the efficacy of Litramine, a similar product, named IQV04, is developed for dogs to support weight loss. The objective of this study was to evaluate the efficacy of IQV04 for weight loss in overweight and obese dogs. Materials and methods: Nineteen colony dogs were randomly divided in three groups, in this placebo controlled and double-blinded study. All dogs received once a day a standardised maintenance meal for their resting energy requirement (RER) with one of the three pills (IQV04 concentration A, IQV04 concentration B and placebo). Body weight and pelvic circumference were measured weekly. By start and end of the study, physical examination, body condition score, complete blood count, serum biochemical analysis and fecal examination was done. Results: Results suggested that there was a difference in body weight reduction between the three groups. The rate of weight loss in the placebo, IQV04 concentration A and IQV04 concentration B group were 2.45 ± 0.51, 2.85 ± 1.84 and 3.03 ± 1.26% body weight reduction per week, respectively. However, this difference did not reach significance. Also there was no significant difference found in pelvic circumference reduction per week. Conclusion: Further studies with larger patient pool are required to achieve more statistic power.
    [Show full text]
  • Small Animal Formulary 6Th Edition
    BSAVA Small Animal Formulary Ian Ramsey 6th edition Small Animal Formulary 6th edition Editor-in-Chief: Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Published by: British Small Animal Veterinary Association Woodrow House, 1 Telford Way, Waterwells Business Park, Quedgeley, Gloucester GL2 2AB A Company Limited by Guarantee in England. Registered Company No. 2837793. Registered as a Charity. Copyright © 2008 BSAVA First edition 1994 Second edition 1997 Third edition 1999 Reprinted with corrections 2000 Fourth edition 2002 Reprinted with corrections 2003 Fifth edition 2005 Reprinted with corrections 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder. A catalogue record for this book is available from the British Library. ISBN 978 1 905319 11 4 The publishers and contributors cannot take responsibility for information provided on dosages and methods of application of drugs mentioned in this publication. Details of this kind must be verified by individual users from the appropriate literature. Printed by: HSW Print, Rhondda, Wales. ii BSAVA Small Animal Formulary 6th edition Other titles from BSAVA: Manual of Canine & Feline Abdominal Surgery Manual of Canine & Feline Anaesthesia and Analgesia Manual of Canine & Feline Behavioural Medicine Manual
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Metabolic Disease
    Metabolic Disease Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models. www.MedChemExpress.com 1 Metabolic Disease Inhibitors & Modulators (-)-(S)-Equol (-)-Fucose Cat. No.: HY-100583 (6-Desoxygalactose; L-(-)-Fucose; L-Galactomethylose) Cat. No.: HY-N1480 Bioactivity: (-)-(S)-Equol is a high affinity ligand for estrogen receptor Bioactivity: (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure β with a Ki of 0.73 nM. determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. Purity: 99.82% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg 100 mg (-)-PX20606 trans isomer (24R)-MC 976 ((-)-PX-102 trans isomer; (-)-PX-104) Cat. No.: HY-100443B Cat. No.: HY-15267A Bioactivity: (-)-PX20606 trans isomer is a FXR agonist with EC50s of 18 Bioactivity: (24R)-MC 976 is a Vitamin D3 derivative. and 29 nM for FXR in FRET and M1H assay, respectively.
    [Show full text]
  • Small Animal Obesity: Effective Control, Management and Care
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk SMALL ANIMAL OBESITY: EFFECTIVE CONTROL, MANAGEMENT AND CARE Author : Catherine F Le Bars Categories : Vets Date : February 23, 2009 Catherine F Le Bars explains how the battle of the bulge and the medical implications specific to certain species need a careful approach to both owner and pet OBESITY is one of the most common nutrition-related conditions in companion animals in the industrialised world, and has a proven association with the development of several disease conditions and reduced longevity. Since weight gain occurs when daily energy intake exceeds energy expenditure, the prevention of obesity requires strict attention to the animal’s nutrition throughout its life. Obesity treatment may be complicated by many factors, and successful management of the condition relies on rigorous owner compliance. Estimates from around the world put the incidence of obesity in dogs and cats at up to 40 per cent, and a number of risk factors have been implicated in its development. These include breed, age, gender, neutering, medication (anti-convulsants, glucocorticoids and contraceptives), lifestyle and exercise, co-existing disease (diabetes mellitus, hypothyroidism, hyperadrenocorticism) and diet. The regulation of food intake is dependent on a complex balance of long-term and shortterm signals to the brain, which are aimed at controlling the fat mass of the animal. When this balance is disrupted, the animal consumes energy above its requirements and gains weight. There are three recognised stages of weight gain: 1 / 10 • A “static ” pre-obesity stage, whereby energy intake is increased but bodyweight remains the same.
    [Show full text]